Glipizide
- TRADE NAMES: Glibenese; Glipid; Glucotrol (Pfizer); Glyde; Melizide; Metaglip (Bristol-Myers Squibb); Mindiab; Minidiab; Minodiab
- INDICATIONS: Non-insulin dependent diabetes Type ll
- CLASS: Antidiabetic, Hypoglycemic (antihyperglycemic) agent, Sulfonylurea
- HALF-LIFE: 2–4 hours
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
None known
PREGNANCY CATEGORY: C
Glipizide is a sulfonamide and can be absorbed systemically. Sulfonamides can produce severe, possibly fatal, reactions such as toxic epidermal necrolysis and Stevens-Johnson syndrome.
Please login to see the rest of this drug profile
SKIN.
MUCOSAL.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
GENITOURINARY.
NEUROMUSCULAR/SKELETAL.
RESPIRATORY.
OTHER.
Page last updated 07/31/2023
Symbol key
Incidence
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric